Tenax Therapeutics (NASDAQ:TENX) Earns Sell Rating from Analysts at StockNews.com

StockNews.com began coverage on shares of Tenax Therapeutics (NASDAQ:TENXGet Rating) in a research report sent to investors on Monday. The brokerage issued a sell rating on the specialty pharmaceutical company’s stock.

Tenax Therapeutics Price Performance

NASDAQ:TENX opened at $0.14 on Monday. The business’s fifty day moving average price is $0.15 and its 200 day moving average price is $0.31. Tenax Therapeutics has a 12 month low of $0.08 and a 12 month high of $1.46.

Hedge Funds Weigh In On Tenax Therapeutics

A hedge fund recently raised its stake in Tenax Therapeutics stock. Armistice Capital LLC grew its position in shares of Tenax Therapeutics, Inc. (NASDAQ:TENXGet Rating) by 23.1% during the 3rd quarter, according to the company in its most recent disclosure with the SEC. The fund owned 1,965,885 shares of the specialty pharmaceutical company’s stock after purchasing an additional 368,836 shares during the quarter. Armistice Capital LLC owned approximately 7.80% of Tenax Therapeutics worth $334,000 as of its most recent filing with the SEC. Institutional investors and hedge funds own 41.94% of the company’s stock.

About Tenax Therapeutics

(Get Rating)

Tenax Therapeutics, Inc, a specialty pharmaceutical company, engages in identifying, developing, and commercializing products for cardiovascular and pulmonary diseases in the United States and Canada. It develops TNX-103 and TNX-102 (levosimendan) that have completed phase II clinical trials for the treatment of patients with pulmonary hypertension associated with heart failure with preserved ejection fraction and associated pulmonary hypertension; and TNX-201 (imatinib), a tyrosine kinase inhibitor for the treatment of pulmonary arterial hypertension.

Recommended Stories

Receive News & Ratings for Tenax Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tenax Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.